Zacks Research Downgrades Phibro Animal Health (NASDAQ:PAHC) to Hold

Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Bank of America raised their target price on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research report on Friday, August 29th. Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. boosted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Morgan Stanley set a $34.00 price target on Phibro Animal Health in a report on Thursday, August 28th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and an average price target of $31.40.

Phibro Animal Health Stock Down 0.5%

PAHC traded down $0.23 during trading hours on Monday, hitting $45.60. 4,702 shares of the company’s stock were exchanged, compared to its average volume of 278,343. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. Phibro Animal Health has a 12-month low of $16.16 and a 12-month high of $46.42. The firm has a market cap of $1.85 billion, a P/E ratio of 38.86, a price-to-earnings-growth ratio of 1.24 and a beta of 0.81. The firm has a 50 day moving average of $40.06 and a 200 day moving average of $31.43.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Analysts predict that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 38,303 shares of Phibro Animal Health stock in a transaction on Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the transaction, the chief executive officer owned 20,577 shares in the company, valued at $931,932.33. This trade represents a 65.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 109,159 shares of company stock valued at $4,620,198 in the last ninety days. 50.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Large investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in Phibro Animal Health by 2.6% in the first quarter. Principal Financial Group Inc. now owns 101,356 shares of the company’s stock valued at $2,165,000 after buying an additional 2,573 shares during the period. Jackson Creek Investment Advisors LLC acquired a new position in shares of Phibro Animal Health during the 1st quarter valued at $1,411,000. Hussman Strategic Advisors Inc. boosted its position in Phibro Animal Health by 20.0% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 126,000 shares of the company’s stock worth $2,691,000 after purchasing an additional 21,000 shares during the period. Csenge Advisory Group increased its holdings in Phibro Animal Health by 26.4% in the 1st quarter. Csenge Advisory Group now owns 26,143 shares of the company’s stock valued at $558,000 after purchasing an additional 5,456 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Phibro Animal Health during the first quarter worth about $331,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.